The CAR-T industry is still in its infancy and I realized there were still many imperfections with the technology
In Conversation
The key success factor to answer [biotech companies'] needs is reactivity and, as a mid-size business, we have the flexibility to work with them efficiently
We are taking a well-established international model of elderly care and bringing it into China, where there is a great need for such elderly care
For any business to be successful in a foreign country, it needs to hire local talent with the knowledge and know-how to meet the needs of…
The Korean beauty regimen is very sophisticated. Local companies understand the needs of Korean consumers and constantly innovate to answer them. For a multinational company to…
Between Mangar and Winncare, the vast majority of our sales are still based in Europe. Our next focus market is absolutely the North American region
Within this year, we are hoping to list our company on the stock market and license-out our treatment for ophthalmological diseases
Many [biotech] companies are obliged to leave France or be bought out by Big Pharma, making it impossible to create the next big French success story
In the past few years, conference centres have grown like mushrooms, which has led to a ten percent increase for the city in terms of economic…
The big question in AI is how to get data and who the data belongs to
The best way to achieve an even better reputation is through obtaining international certifications
Cellectis is working to develop the concept of off-the-shelf, gene edited UCART cells – universal CAR-T
